Biosimilar expansion

Discussion in 'Pfizer' started by anonymous, Aug 11, 2016 at 12:33 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    This position was with Hospira a year ago.....finally moving forward. Has anyone received a call from the manager? When do interviews start? Posting closed on the 9th I think??
     

  2. anonymous

    anonymous Guest

    Dont quit your day job. This division is a train wreck waiting to happen. No product, clueless management, and a true shit show.
     
  3. anonymous

    anonymous Guest

     
  4. anonymous

    anonymous Guest

    really a shit show? Give some examples...
     
  5. anonymous

    anonymous Guest

    I think opportunity could be a good one. I would definitely look into it. Biosimilars are coming soon and Pfizer is the leader in the Field. Don't miss out!
     
  6. anonymous

    anonymous Guest

    Only issue with this division is I foresee is that it just becomes a pricing war with all the other "me too's" that arrive in short order. I think the efficacy and safety of these generics will be the last thing on most of our customers' minds. At that point, what are we really accomplishing? Hope I'm wrong.
     
  7. anonymous

    anonymous Guest

    The very short posting time is a clear sign. They plan to hire from outside. PC need not apply
     
  8. anonymous

    anonymous Guest

    It will all come down to price just like in the EU. The bigger question is why would anyone take a risk on a biosimilar, when the originator will likely be competitive on price down to ~30%. Thus the reason why biosimilars will have to dig deep in discount, which raises questions of sustainable promotional ROI.
     
  9. anonymous

    anonymous Guest

    A marketing team with no extensive biologic, inflammation, oncology, or buy and bill experience. They are all a mixture of inexperienced Hospira & old school Pfizer Established Product dinosaurs.
     
  10. anonymous

    anonymous Guest

    Sounds like the classic, modern Pfizer marketing team: out of touch, clueless, and quite delusional.
     
  11. anonymous

    anonymous Guest

    Hahahahahahahaha! Almost pissed my pants on this one. Drink some more kool-aid.
     
  12. anonymous

    anonymous Guest

    Exactly, and well said. It's a commodity that will be sold on price alone.
     
  13. anonymous

    anonymous Guest

    No, it's classic Pfizer from day one. Its always been this way, know nothing cheerleaders rah, rahing about nothing. So far removed from the real world they're lost. They lose at Pokeman.
     
  14. anonymous

    anonymous Guest

    Seriously, do I really have to list them for you? You can't be that stupid.
    Dyloject is a reject. Our "leaders" are a joke. Third rate rejects.
    No market for Dyloject. A dangerous and expensive "me too"
    If that's not enough, let me know.
     
  15. anonymous

    anonymous Guest

     
  16. anonymous

    anonymous Guest

    Got an email today, phone screen next week. anyone know particulars? who are they looking for? base? Bonus?
     
  17. anonymous

    anonymous Guest

    Looking for mindless idiots who do what they are told. 110-130 base. Bonus is anyones guess. Pfizer changes it as we go, down. Management is second rate rejects fro other companies.
     
  18. anonymous

    anonymous Guest

    Amgen toads!
     
  19. anonymous

    anonymous Guest

    I was told expect a call this week to schedule face to face interview. Has anyone scheduled face to face yet?
     
  20. anonymous

    anonymous Guest

    No have not heard anything, has anyone else